![](/img/cover-not-exists.png)
462 Intravenous and oral ibandronate reduce the risk of skeletal related events in patients with metastatic bone disease
J.-J. Body, D. Tripathy, M. Pecherstorfer, B. BergstromVolume:
1
Year:
2003
Language:
english
DOI:
10.1016/s1359-6349(03)90494-0
File:
PDF, 156 KB
english, 2003